Cas:68333-79-9 Ammonium polyphosphate manufacturer & supplier

Chemical Name:Ammonium polyphosphate

CAS.NO:68333-79-9

Synonyms:Ammonium monophosphate;Triammonium phosphate;ammonium phosphate;Ammonium polyphosphate;EINECS 269-789-9

Molecular Formula:H₁₂N₃O₄P

Molecular Weight:149.087

HS Code:2835399000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:97.29000

Exact Mass:149.056549

LogP:0.04310

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Ammonium monophosphate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 269-789-9 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 269-789-9 Use and application,Triammonium phosphate technical grade,usp/ep/jp grade.

Related News: Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. Ammonium polyphosphate manufacturer Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey. Ammonium polyphosphate supplier Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. Ammonium polyphosphate vendor Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey. Ammonium polyphosphate factory Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey.